Skip to main content

Table 2 Potential epigenetic chemotherapies for oropharyngeal carcinoma

From: Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets

Chemotherapeutic Agent Status Reference
DNMT inhibitors
 Arsenic trioxide Clinical Trials [112]
 5- azacytidine (Vidaza, Celgene) USFDA Approved [47]
 5-aza-2′-deoxycitidine (Decitabine, Dacogen, SuperGen) USFDA Approved [47]
 MG98 Clinical trials [122]
HDAC inhibitors
 LAQ-824/LBH 589 (Farydak, panobinostat) USFDA Approved [122]
 PXD-101(Belinostat) Clinical trials [122]
 Valproic acid (Mg valproate) Clinical trials [122]
 Suberoylanilide hydroxamic acid (vorinostat, SAHA) USFDA Approved [122]
 FK-228 (romidepsin) USFDA Approved [121]
 Phenylbutyrate Clinical trials [122]
 MS-275 (entinostat) Clinical trials [150, 151]
 CI-994 Clinical trials [90, 120]
 MGCD-0103 (Mocetinostat) Clinical trials [145]
 JNJ-26481585 (Quisinostat) Clinical trials [146, 147]
HMT inhibitors
 EPZ-6438 (E7438, Epizyme) Clinical trials [62, 148]
 3-Deazaneplanocin (DZNep) Clinical trials [58]
 EPZ-5676 Clinical trials [62]
 EPZ-5687 Preclinical [58]
 GSK-343 Preclinical [58]
  1. DZNep, 3-deazaneplanocin A; USFDA United States Food and Drug Association